In eagerly awaited results from a new study, the pharmaceutical company Eli Lilly reports that a pill its scientists ...

Eli Lilly's new oral GLP-1 medication orforglipron produced an average weight loss of 12.4% (27.3 pounds) in clinical trials.

Eli Lilly said will raise the UK list price of its weight-loss treatment Mounjaro by up to 170%, amid a White House push to ...

Lilly is still worth over $500 billion, but its market capitalisation has shed almost a third in the past year. With ...

Lilly's second-quarter results reported Thursday were still more than fine: $15.5 billion in revenue beat Wall Street ...

The company said it planned to seek Food and Drug Administration approval for the drug, orforglipron, before the end of the ...

Eli Lilly is one step closer to bringing an oral weight loss medicine to the booming obesity drug market. A clinical trial ...

Eli Lilly, the maker of the popular injectable Mounjaro, has just released the surprising phase 3 trial results for its new ...

Viking Therapeutics stock tumbled after the drugmaker released study results of its experimental weight-loss pill.

Eli Lilly is investing a further $5.3 billion (€4.9 billion) in a new US manufacturing site, one of the biggest investments of its kind, to boost production of its hugely popular diabetes and ...

Eli Lilly will spend $5.3bn (€4.9bn) to boost production of a key ingredient in its weight-loss and diabetes shots after the treatments’ explosive popularity led to shortages. The ...

Companies Eli Lilly vies to join $1trn stock market club with Zepbound weight loss drug Zepbound, which was recently approved for weight loss, is predicted to become the best-selling drug in history ...